Additive endocrine therapy for advanced breast cancer – back to the future

@article{Lnning2009AdditiveET,
  title={Additive endocrine therapy for advanced breast cancer – back to the future},
  author={Per Eystein L{\o}nning},
  journal={Acta Oncologica},
  year={2009},
  volume={48},
  pages={1092 - 1101}
}
  • P. Lønning
  • Published 1 January 2009
  • Medicine
  • Acta Oncologica
While novel endocrine treatment options have been implemented in the advanced – as well as adjuvant setting, recent results suggest a place for “old-fashioned” additive treatment with estrogens in advanced breast cancer. This paper reviews the biological rationale for endocrine therapy in general and additive treatment with estrogens in particular. The finding that patients becoming resistant to treatment with aromatase inhibitors may subsequently respond to estrogen therapy adds important… 
Evolution of endocrine adjuvant therapy for early breast cancer
  • P. Lønning
  • Medicine
    Expert opinion on investigational drugs
  • 2010
TLDR
The objective of this paper is to critically review endocrine treatment options in early breast cancer focusing on ongoing development, and particular attention is paid to the topic of HER-2 expression as a potential cause of endocrine resistance.
A review of the treatment of endocrine responsive metastatic breast cancer in postmenopausal women.
TLDR
This review evaluates the available evidence supporting the use of endocrine therapy for the treatment of hormone receptor-positive MBC, and considers the effect of prior adjuvant therapy on treatment choice in the metastatic setting and the optimal treatment sequence.
Ineffective Inhibition of Aromatase: A Cause for AI Resistance?
TLDR
These findings do not exclude the possibility that in some patients intratumour aromatase to some degree may escape inhibition; however, due to rapid equilibrium with the plasma pool, such a phenomenon most likely should have limited effect on intratumoursal estrogen levels.
Androgen receptor in estrogen receptor positive breast cancer: Beyond expression.
TLDR
It is crucial to identify biomarkers that would enable the selection of patients who might benefit from combination treatment with ER and AR inhibitors, and to identify targets that seem to be involved in resistance to hormonal treatment.
Activity of megestrol acetate in postmenopausal women with advanced breast cancer after nonsteroidal aromatase inhibitor failure: a phase II trial.
TLDR
This is the first study to prospectively evaluate the efficacy and safety of Megestrol acetate in postmenopausal women with hormone-sensitive disease progressing on a third-generation nonsteroidal aromatase inhibitor (NSAI).
High-dose toremifene as first-line treatment of metastatic breast cancer resistant to adjuvant aromatase inhibitor: A multicenter phase II study.
TLDR
High-dose TOR as a first-line treatment following AI adjuvant therapy was effective and well tolerated and may, with further studies, be beneficial as positive predictive factors for the effectiveness of TOR treatment.
Androgen Receptor Function and Androgen Receptor–Targeted Therapies in Breast Cancer: A Review
TLDR
In-depth understanding of AR and AR-related signaling pathways would improve the treatment strategies for AR-positive breast cancer and inform the development of AR-targeted therapies to improve survival outcome in patients with breast cancer.
Androgen and Estrogen Receptors in Breast Cancer. Impact on Risk, Prognosis and Treatment Prediction.
TLDR
A clinical implementation could be possible for both AR and ERβ in the near future, provided better insights into their roles in breast cancer development and treatment.
The molecular, cellular and clinical consequences of targeting the estrogen receptor following estrogen deprivation therapy
TLDR
The current understanding of the mechanism of estrogen-induced apoptosis is described as a consequence of acquired resistance to long term antihormone therapy in estrogen receptor (ER) positive breast cancer.
The St. Gallen Prize Lecture 2011: evolution of long-term adjuvant anti-hormone therapy: consequences and opportunities.
The successful translation of the scientific principles of targeting the breast tumour oestrogen receptor (ER) with the nonsteroidal anti-oestrogen tamoxifen and using extended durations (at least 5
...
1
2
3
4
...

References

SHOWING 1-10 OF 109 REFERENCES
High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy
TLDR
The results reveal estrogens administered in high doses may have antitumor effects in breast cancer patients heavily pretreated with endocrine therapy, and represents a valuable alternative to chemotherapy in selected patients.
High dose estrogen as a salvage hormonal strategy for highly refractory metastatic breast cancer (MBC): “back to the future.”.
TLDR
Almost all patients with hormone receptor (+) MBC eventually develop resistance to endocrine agents, and data confirm the efficacy of high dose estrogens as yet another option for heavily-treated patients in whom further endocrine manipulation might still be appropriate.
Endocrine treatment of breast cancer in women.
TLDR
When hormone receptor measurements were introduced in the mid-1970s, better selection of patients with hormonally responsive tumors became possible, and new impetus was provided for optimizing hormonality responsive tumors.
High-dose megestrol acetate for the treatment of advanced breast cancer: dose and toxicities.
TLDR
Evaluated the tolerability and toxicity of escalating doses of megestrol acetate found mild BP elevation, weight gain, increased appetite, hyperglycemia, edema, dyspnea, congestive heart failure, and other mild problems.
Aromatase inhibitors: Future directions
  • C. Osborne, R. Schiff
  • Biology, Medicine
    The Journal of Steroid Biochemistry and Molecular Biology
  • 2005
TLDR
Advanced experimental studies and some clinical observations reveal the importance of blocking both the genomic and non-genomic activities of the estrogen receptor, as well as its crosstalk with growth factor and other cellular signaling, for greatest effectiveness of endocrine therapy.
Mechanisms of action of endocrine treatment in breast cancer.
TLDR
Exploration of different aromatase inhibitors in sequence or concert, as well as the combining of different endocrine treatment options may be warranted, and alterations in different biochemical parameters such as growth factors should not only be carefully explored in relation to treatment options but should also be followed during the course of treatment.
Effects of intensive sex steroid hormone therapy in advanced breast cancer.
TLDR
The duration of treatment varied from a few days to several years, and Deleterious reactions occurred early in some patients, necessitating discontinuance of therapy, so effects that might have occurred at later intervals could not be recorded.
Multicenter, Phase II Trial of Exemestane as Third-Line Hormonal Therapy of Postmenopausal Women With Metastatic Breast Cancer
TLDR
To assess the antitumor activity, safety, and hormone-suppressive effects of the irreversible aromatase inactivator, exemestane, administered as third-line hormone therapy to postmenopausal women with metastatic breast cancer that is refractory to tamoxifen and megestrol acetate, ninety-one patients were treated.
BENEFICIAL EFFECT OF ADJUVANT TAMOXIFEN THERAPY IN PRIMARY BREAST CANCER PATIENTS WITH HIGH OESTROGEN RECEPTOR VALUES
TLDR
Oestrogen receptor concentrations were measured in primary tumours of 291 postmenopausal breast cancer patients with high risk of recurrence and showed that patients with an oestrogen-receptor content below 100 f Mol/mg did not benefit from the endocrine therapy, while those with concentrations above 100 fmol/mg had a significantly longer recurrence-free survival.
Randomized trial of estrogen vs. tamoxifen therapy for advanced breast cancer
TLDR
Initial hormonal therapy with tamoxifen in postmenopausal patients with advanced breast cancer and ERP status positive or unknown is superior to primary estrogen treatment.
...
1
2
3
4
5
...